PMID- 24631482
OWN - NLM
STAT- MEDLINE
DCOM- 20150105
LR  - 20220318
IS  - 1878-7436 (Electronic)
IS  - 1878-7436 (Linking)
VI  - 8
IP  - 5
DP  - 2014 May
TI  - Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors.
PG  - 330-9
LID - S1933-1711(14)00060-6 [pii]
LID - 10.1016/j.jash.2014.02.003 [doi]
AB  - Management of hypertension in diabetes is critical for reduction of 
      cardiovascular mortality and morbidity. While blood pressure (BP) control has 
      improved over the past two decades, the control rate is still well below 50% in 
      the general population of patients with type 2 diabetes mellitus (T2DM). A new 
      class of oral glucose-lowering agents has recently been approved; the 
      sodium-glucose co-transporter 2 (SGLT2) inhibitors, which act by eliminating 
      large amounts of glucose in the urine. Two agents, dapagliflozin and 
      canagliflozin, are currently approved in the United States and Europe, and 
      empagliflozin and ipragliflozin have reported Phase 3 trials. In addition to 
      glucose lowering, SGLT2 inhibitors are associated with weight loss and act as 
      osmotic diuretics, resulting in a lowering of BP. While not approved for 
      BP-lowering, they may potentially aid BP goal achievement in people within 7-10 
      mm Hg of goal. It should be noted that the currently approved agents have side 
      effects that include an increased incidence of genital infections, predominantly 
      in women. The approved SGLT2 inhibitors have limited use based on kidney function 
      and should be used only in those with an estimated glomerular filtration rate 
      (eGFR) > 60 mL/min/1.73 m2 for dapagliflozin and >/=45 mL/min/1.73 m2 for 
      canagliflozin. Cardiovascular outcome trials are ongoing with these agents and 
      will be completed within the next 4-5 years.
CI  - Copyright (c) 2014 American Society of Hypertension. Published by Elsevier Inc. All 
      rights reserved.
FAU - Oliva, Raymond V
AU  - Oliva RV
AD  - Department of Medicine, Philippine General Hospital, Manila, Philippines.
FAU - Bakris, George L
AU  - Bakris GL
AD  - ASH Comprehensive Hypertension Center, The University of Chicago Medicine, 
      Chicago, IL, USA. Electronic address: gbakris@medicine.bsd.uchicago.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20140212
PL  - United States
TA  - J Am Soc Hypertens
JT  - Journal of the American Society of Hypertension : JASH
JID - 101312518
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Blood Glucose)
RN  - 0 (Glucosides)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0 (Thiophenes)
RN  - 0SAC974Z85 (Canagliflozin)
RN  - 1ULL0QJ8UC (dapagliflozin)
RN  - HDC1R2M35U (empagliflozin)
SB  - IM
MH  - Benzhydryl Compounds/therapeutic use
MH  - Blood Glucose/metabolism
MH  - Blood Pressure/*drug effects/physiology
MH  - Body Weight/drug effects
MH  - Canagliflozin
MH  - Glucosides/therapeutic use
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Kidney/physiology
MH  - Renal Reabsorption/drug effects/physiology
MH  - *Sodium-Glucose Transporter 2 Inhibitors
MH  - Thiophenes/therapeutic use
OTO - NOTNLM
OT  - Diabetes
OT  - SGLT2
OT  - glucose
OT  - hypertension
OT  - transporters
EDAT- 2014/03/19 06:00
MHDA- 2015/01/06 06:00
CRDT- 2014/03/18 06:00
PHST- 2014/01/30 00:00 [received]
PHST- 2014/02/03 00:00 [revised]
PHST- 2014/02/04 00:00 [accepted]
PHST- 2014/03/18 06:00 [entrez]
PHST- 2014/03/19 06:00 [pubmed]
PHST- 2015/01/06 06:00 [medline]
AID - S1933-1711(14)00060-6 [pii]
AID - 10.1016/j.jash.2014.02.003 [doi]
PST - ppublish
SO  - J Am Soc Hypertens. 2014 May;8(5):330-9. doi: 10.1016/j.jash.2014.02.003. Epub 
      2014 Feb 12.